However, Ichihara E. et al. reported that in EGFR-mutated NSCLC patients, PFS of the subjects with higher BSA was significantly worse than that of those with lower BSA and consequently postulated that blood concentrations were reversely correlated with BSA and then influenced the gefitinib response7. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.